IKT Earnings Forecast
Looking ahead, IKT remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.13.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.38%, while EPS estimates have been Go Up by 6.52%. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in IKT long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
EPS Estimates for FY2025
Revise Upward
+0.38%
In Past 3 Month
Stock Price
Go Up
+6.52%
In Past 3 Month
Unlock the reason behind revisions!
No data
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how IKT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IKT sees a -4.03% change in stock price 10 days leading up to the earnings, and a -2.91% change 10 days following the report. On the earnings day itself, the stock moves by +1.96%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -4.38% on the day following the earnings release and then changed by -5.00% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of IKT's latest earnings report for ?
IKT reported its earnings on 2025-11-13, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a -4.38% price change on the earnings day and a -2.5% change over the next five days, reflecting market reactions to the results.
How did IKT's stock price react after the earnings release?
Following IKT's earnings announcement on 2025-11-13, the stock price moved by -4.38% on the day of the release. Over the subsequent five days, it saw a -2.50% change. Historically, IKT's stock price tends to shift by an average of -4.03% in the 10 days leading up to earnings and -2.91% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for IKT for undefined?
For , analysts estimate IKT’s annual revenue to reach , while the EPS is projected at -0.13. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.38% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.
How does IKT's stock price correlate with earnings forecast revisions?
The correlation between IKT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.38%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from IKT's next earnings report?
Based on historical trends, IKT's stock price typically moves by -4.03% in the 10 days before its earnings and -2.91% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.13 and revenue of .
What is the sentiment in Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Summary?
The earnings call presents a mixed picture. Financial performance shows a decrease in net loss and R&D expenses, indicating cost management. However, funding challenges and reliance on FDA approval pose risks. The market opportunity in PAH is significant, but competitive. Q&A reveals uncertainties in trial timelines and patient transitions. Overall, the lack of clear guidance and potential funding issues balance out positive developments, resulting in a neutral sentiment.